ダウンロード数: 1360
タイトル: | ナフトピジル抵抗性の夜間頻尿を有する前立腺肥大症に対するプロピベリン併用の効果 |
その他のタイトル: | Additional Effect of Propiverine for Naftopidil-Resistant Nocturia in the Patient with Benign Prostate Hypertrophy |
著者: | 神村, 典孝 畠山, 真吾 工藤, 茂将 米山, 高弘 橋本, 安弘 古家, 琢也 吉川, 和暁 川口, 俊明 高橋, 伸也 大山, 力 |
著者名の別形: | Kamimura, Noritaka Hatakeyama, Shingo Kudo, Shigemasa Yoneyama, Takahiro Hashimoto, Yasuhiro Koie, Takuya Yoshikawa, Kazuaki Kawaguchi, Toshiaki Takahashi, Shinya Ohyama, Chikara |
キーワード: | Benign prostatic hypertrophy Nocturia Propiverine Naftopidil |
発行日: | Feb-2011 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 57 |
号: | 2 |
開始ページ: | 71 |
終了ページ: | 76 |
抄録: | The efficacy and safety of additional administration of propiverine were prospectively studied for naftopidil-resistant nocturia in patients with benign prostatic hypertrophy (BPH). Patients of 50 years and over with BPH who experienced nocturia twice a night or more and an overall International Prostate Symptom Score (IPSS) of 8 or more were first administered naftopidil (50 or 75 mg/day) for 4 weeks. Thirty subjects who did not show improvement in nocturia and requested further treatment were enrolled in the present study. Propiverine was then administered concomitantly 10 mg/day for 8 weeks. Significant improvement was observed with additional propiverine in the frequency of nocturia on voiding diary, total IPSS, voiding symptom, storage symptom and nocturnal voiding scores. No significant change was observed in the peak urinary flow rate (Qmax), mean urinary flow rate (Qave), voided urine volume, or residual urine volume. Adverse events were dysuria (2 cases), increased residual urine (6 cases), weak urine flow (1 case), thirsty (2 cases), angular cheilitis (1 case). Administration of propiverine was suspended in 7 subjects, 1 following dysuria and 6 following increased residual urine volume. The suspension of propiverine following increased residual urine volume was significantly more prevalent in subjects with pretreatment Qmax values of less than 10 ml/second or in subjects whose prostate specific antigen (PSA) levels were 2 ng/ml or more. In conclusion, the results indicate that additional administration of propiverine may be useful for the patients with BPH who have naftopidil-resistant nocturia. However, caution must be exercised regarding Qmax and PSA levels. |
著作権等: | 許諾条件により本文は2012-03-01に公開 |
URI: | http://hdl.handle.net/2433/138600 |
PubMed ID: | 21412038 |
出現コレクション: | Vol.57 No.2 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。